Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: Interim analysis of an open-label, parallel-group, phase 2 study

The Lancet Oncology

Volumn 14, Issue 9, 2013, Pages 901-908

  Chawla, Sant ^a   Henshaw, Robert ^b   Seeger, Leanne ^c   Choy, Edwin ^d   Blay, Jean Yves ^e   Ferrari, Stefano ^f   Kroep, Judith ^g   Grimer, Robert ^h   Reichardt, Peter ⁱ   Rutkowski, Piotr ^j   Schuetze, Scott ^k   Skubitz, Keith ^l   Staddon, Arthur ^m   Thomas, David ⁿ   Qian, Yi ^o   Jacobs, Ira ^o  

^a Sarcoma Oncology Center   (United States)

^b GEORGETOWN UNIVERSITY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e UNIVERSITÉ LYON 1   (France)

^f RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

^g LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^h ROYAL ORTHOPAEDIC HOSPITAL   (United Kingdom)

ⁱ HELIOS KLINIKUM BERLIN BUCH   (Germany)

^j INSTITUTE OF ONCOLOGY   (Poland)

^k UNIVERSITY OF MICHIGAN   (United States)

^l UNIVERSITY OF MINNESOTA   (United States)

^m Pennsylvania Oncology Hematology Associates   (United States)

ⁿ PETER MACCALLUM CANCER CENTRE   (Australia)

^o AMGEN INC   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; DENOSUMAB; VITAMIN D;

ADOLESCENT; ADULT; ARTHRALGIA; ARTICLE; BACKACHE; BONE MATURATION; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CHEMOTHERAPY INDUCED ANEMIA; CHILD; COHORT ANALYSIS; DEPRESSION; DISEASE COURSE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; FATIGUE; FEMALE; FOLLOW UP; HUMAN; HYPOCALCEMIA; HYPOPHOSPHATEMIA; INFECTION; JAW OSTEONECROSIS; LIMB PAIN; LOADING DRUG DOSE; LONG BONE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MULTIPLE CYCLE TREATMENT; MUSCULOSKELETAL PAIN; NAUSEA; OPEN STUDY; OSTEOCLASTOMA; OSTEOMYELITIS; PARALLEL DESIGN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SALVAGE THERAPY; SCHOOL CHILD; SIDE EFFECT; TREATMENT OUTCOME; WEIGHT GAIN;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; BONE NEOPLASMS; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; GIANT CELL TUMOR OF BONE; HUMANS; INTERNATIONAL AGENCIES; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; YOUNG ADULT;

EID: 84880770534     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(13)70277-8     Document Type: Article

References (25)

1. Mendenhall WM, Zlotecki RA, Scarborough MT, Gibbs CP, Mendenhall NP Giant cell tumor of bone. Am J Clin Oncol 2006, 29:96-99.
2. Gupta R, Seethalakshmi V, Jambhekar NA, et al. Clinicopathologic profile of 470 giant cell tumors of bone from a cancer hospital in western India. Ann Diagn Pathol 2008, 12:239-248.
3. Alberghini M, Kliskey K, Krenacs T, et al. Morphological and immunophenotypic features of primary and metastatic giant cell tumour of bone. Virchows Arch 2010, 456:97-103.
4. Szendroi M Giant-cell tumour of bone. J Bone Joint Surg Br 2004, 86:5-12.
5. Bone tumors-benign Civista Health Library, (accessed June 15, 2012). http://www.health-news-and-information.com/4civista/libv/c33.shtml.
6. DeVita V, Lawrence TS, Rosenberg SA DeVita, Hellman, and Rosenberg's cancer: principles and practices of oncology 2008, Lippincott, Williams, and Wilkins, Philidelphia.
7. Thomas DM, Skubitz KM Giant cell tumor of bone. Curr Opin Oncol 2009, 21:338-344.
8. Garcia RA, Inwards CY, Unni KK Benign bone tumors-recent developments. Semin Diagn Pathol 2011, 28:73-85.
9. Balke M, Campanacci L, Gebert C, et al. Bisphosphonate treatment of aggressive primary, recurrent and metastatic giant cell tumour of bone. BMC Cancer 2010, 10:462.
10. Atkins GJ, Kostakis P, Vincent C, et al. RANK expression as a cell surface marker of human osteoclast precursors in peripheral blood, bone marrow, and giant cell tumors of bone. J Bone Miner Res 2006, 21:1339-1349.
11. Goldring SR, Roelke MS, Petrison KK, Bhan AK Human giant cell tumors of bone identification and characterization of cell types. J Clin Invest 1987, 79:483-491.
12. Huang L, Xu J, Wood DJ, Zheng MH Gene expression of osteoprotegerin ligand, osteoprotegerin, and receptor activator of NF-kappaB in giant cell tumor of bone: possible involvement in tumor cell-induced osteoclast-like cell formation. Am J Pathol 2000, 156:761-767.
13. Roux S, Amazit L, Meduri G, Guiochon-Mantel A, Milgrom E, Mariette X RANK (receptor activator of nuclear factor kappa B) and RANK ligand are expressed in giant cell tumors of bone. Am J Clin Pathol 2002, 117:210-216.
14. Skubitz KM, Cheng EY, Clohisy DR, Thompson RC, Skubitz AP Gene expression in giant-cell tumors. J Lab Clin Med 2004, 144:193-200.
15. Liao TS, Yurgelun MB, Chang SS, et al. Recruitment of osteoclast precursors by stromal cell derived factor-1 (SDF-1) in giant cell tumor of bone. J Orthop Res 2005, 23:203-209.
16. Lau YS, Sabokbar A, Gibbons CL, Giele H, Athanasou N Phenotypic and molecular studies of giant-cell tumors of bone and soft tissue. Hum Pathol 2005, 36:945-954.
17. Branstetter DG, Nelson SD, Manivel JC, et al. Denosumab induces tumor reduction and bone formation in patients with giant-cell tumor of bone. Clin Cancer Res 2012, 18:4415-4424.
18. Thomas D, Henshaw R, Skubitz K, et al. Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study. Lancet Oncol 2010, 11:275-280.
19. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1·1). Eur J Cancer 2009, 45:228-247.
20. Young H, Baum R, Cremerius U, et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. Eur J Cancer 1999, 35:1773-1782. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group.
21. Choi H, Charnsangavej C, Faria SC, et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 2007, 25:1753-1759.
22. Stopeck A, Lipton A, Body JJ, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 2010, 28:5132-5139.
23. Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011, 377:813-822.
24. Henry DH, Costa L, Goldwasser F, et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 2011, 29:1125-1132.
25. Lipton A, Fizazi K, Stopeck AT, et al. Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer 2012, 48:3082-3092.